Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, the subsidiaries of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), Chengdu Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd., received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for HRS-8046 tablets and will conduct clinical trials in the near future.

HRS-8046 tablets are an innovative anti-tumor drug independently developed by the company. It is intended to treat solid tumors carrying KRAS G12D mutations. According to inquiries, there are currently no similar drugs on the market at home or abroad. Up to now, the total R&D investment for HRS-8046 film-related projects is about 15.4 million yuan (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.